VALENANT Pharmaceuticals International
bromide tablets, USP)
Mestinon (pyridostigmine bromide tablets, USP) is an orally active cholinesterase inhibitor.
Mestinon (pyridostigmine cation) is indicated for the following:
Mestinon is useful in the treatment of myasthenia gravis.
Media Articles Related to Mestinon (Pyridostigmine)
Discovery of most common cause of muscle-weakening disease myasthenia gravis
Source: Muscular Dystrophy / ALS News From Medical News Today [2013.11.13]
An antibody to a protein critical to enabling the brain to talk to muscles has been identified as a cause of myasthenia gravis, researchers report.
Source: MedicineNet rituximab Specialty [2012.10.15]
Title: Myasthenia Gravis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 10/15/2012 12:00:00 AM
New technique for testing drugs to treat cystic fibrosis and epilepsy
Source: Health News from Medical News Today [2013.11.30]
Researchers from the University of Southampton, in collaboration with researchers at the University of Quebec at Montreal, have developed a new microsystem for more efficient testing of pharmaceutical drugs to treat diseases such as cystic fibrosis, MG (myasthenia gravis) and epilepsy.A large percentage of pharmaceutical drugs target ion channels, which are proteins found in a cell's membrane, that play a pivotal role in these serious disorders and that are used to test the effectiveness of new drugs.
Published Studies Related to Mestinon (Pyridostigmine)
Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. [2010.11]
Orthostatic hypotension affects patients with autonomic failure producing considerable disability because of presyncopal symptoms. Severely affected patients may have residual sympathetic tone that can be engaged to increase blood pressure (BP) with the alpha-2 adrenergic antagonist yohimbine.Engaging residual sympathetic tone with yohimbine is a more effective approach to improve orthostatic hypotension as compared with pyridostigmine in patients with severe orthostatic hypotension.
Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in patients infected by HIV. [2009.08]
HIV infection is characterized by persistent immune activation, increased production of proinflammatory cytokines, and rapid T cell turnover...
Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. [2009.07]
3,4-Diaminopyridine and pyridostigmine are widely used to treat Lambert-Eaton myasthenic syndrome (LEMS), either alone or in combination... Therefore, we performed a placebo-controlled, double-dummy, double-blind, randomized, crossover study in nine patients with LEMS.
The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. [2009.03]
BACKGROUND: There is limited information on medications with promotility effects on the esophagus. Studies in healthy volunteers have shown the potential role of the direct cholinergic agonist bethanechol and the serotonin receptor agonist buspirone in improving esophageal motility. It has been also shown that an acetylcholinesterase inhibitor, the short-acting drug edrophonium administered intravenously caused a greater increase in the esophageal contraction amplitude and duration than bethanechol. Edrophonium cannot be used as a promotility therapy owing to short duration of action and lack of oral administration. The use of another acetylcholinesterase inhibitor pyridostygmine with longer duration of action has not been studied. The aim of the study was to evaluate the effect of oral pyridostygmine (60 mg), buspirone (20 mg), and bethanechol (25 mg) on esophageal function assessed by combined multichannel intraluminal impedance-esophageal manometry... CONCLUSIONS: Oral pyridostygmine, buspirone, and bethanechol enhance esophageal motility with pyridostygmine appearing to have the greatest effect. A potential effect on improving esophageal function and symptoms in patients requires further study.
A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. [2008.02]
OBJECTIVE: A subset of fibromyalgia (FM) patients have a dysfunctional hypothalamic-pituitary-insulin-like growth factor 1 (IGF-1) axis, as evidenced by low serum levels of IGF-1 and a reduced growth hormone (GH) response to physiologic stimuli. There is evidence that pyridostigmine (PYD) improves the acute response of GH to exercise in FM patients. The purpose of this study was to evaluate the clinical effectiveness of 6 months of PYD and group exercise on FM symptoms... CONCLUSION: Neither the combination of PYD plus supervised exercise nor either treatment alone yielded improvement in most FM symptoms. However, PYD did improve anxiety and sleep, and exercise improved fatigue and fitness. We speculate that PYD may have improved vagal tone, thus benefiting sleep and anxiety; this notion warrants further study.
Clinical Trials Related to Mestinon (Pyridostigmine)
Droxidopa / Pyridostigmine in Orthostatic Hypotension [Recruiting]
The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural
transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE).
This combination should result in enhanced orthostatic release of NE. The investigators have
already demonstrated that pyridostigmine does not raise supine blood pressure.
Safety Study of Pyridostigmine in Heart Failure [Recruiting]
Heart failure, a common heart disease affecting nearly 6 million Americans, is associated
with high rates of hospitalization and death. Abnormalities in the autonomic nervous system
are thought to play an important role in the progression of heart failure. This proposal
aims to determine whether novel application of pyridostigmine, a drug currently approved by
the FDA only for the treatment of neuromuscular disease, can improve autonomic nervous
system function in heart failure patients.
Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients [Recruiting]
The purpose of the study is to determine if pyridostigmine bromide improves heart rate
variability of type 2 diabetes mellitus subjects with cardiovascular autonomic neuropathy.
Use of Pyridostigmine for Constipation in Diabetics [Recruiting]
Doctors at Mayo Clinic are doing this study to learn if pyridostigmine, a drug, affects the
speed at which food travels through the stomach, intestines and colon, and if pyridostigmine
improves constipation symptoms in patients with diabetes. Pyridostigmine has been approved
by the Food and Drug Administration (FDA) for routine clinical use, however, its use as
proposed in this study is considered investigational.
Testing Mestinon and Exercise in Fibromyalgia [Active, not recruiting]
The purpose of this trial was to test the combined and independent effects of 6 months of
exercise and Mestinon in people with fibromyalgia. Specifically, we wanted to determine if
Mestinon helped people with fibromyalgia have an easier time exercising and if their symptoms
improved by the end of the trial.
Reports of Suspected Mestinon (Pyridostigmine) Side Effects
Cerebrovascular Accident (3),
Myasthenia Gravis (1),
Drug Interaction (1),
Drug Label Confusion (1),
Medication Error (1),
Dizziness (1), more >>
Page last updated: 2013-11-30